Skip to main content
. 2020 Aug 2;12(8):2142. doi: 10.3390/cancers12082142

Figure 1.

Figure 1

Overview of Epstein–Barr virus (EBV) lytic induction therapy. EBV lytic cycle is first reactivated by chemical inducers in which the viral protein kinase encoded by BGLF4 is produced. BGLF4 then activates the nucleoside analogue antiviral pro-drug into its cytotoxic form, and consequently results in a specific killing effect on EBV-positive cells. Moreover, the activated drugs can be transferred to adjacent cells, resulting in a “bystander killing” effect. GCV, valganciclovir.